Specifically, the use of spironolactone, demonstrated a trend towards improved LASr, although the difference did not reach statistical significance in a 2023 study from Girard et al. in patients with resistant hypertension over six months (29.1 ± 8.5% vs. 30.9 ± 5.5% p -value: 0.068) [ 27 ].
1
—
—